Work

Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC

Year: 2021

Type: editorial

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.06.028

Authors: Bin-Chi Liao, James Chih-Hsin Yang

Institutions: National Taiwan University, National Taiwan University Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Novartis, Roche, Takeda Pharmaceutical Company, Daiichi-Sankyo, Ono Pharmaceutical, EMD Serono, Merck Sharp and Dohme, Chugai Pharmaceutical, Janssen Pharmaceuticals

OpenAlex ID: W3195950760

Cites: 16

Cited by:

Related to: 10